TORONTO,
Nov. 13, 2014 /CNW/ - Bioniche Life
Sciences Inc. (TSX: BNC) ("Bioniche" or the
"Company") is pleased to provide the results from its annual
general meeting of shareholders held November 12, 2014 in Toronto (the "Meeting").
At the Meeting, the six nominees proposed by management were
elected to serve as a director of the Company to hold office for
the ensuing year or until his or her successor is elected. One
director did not receive more votes for, than votes which were
withheld, and, in compliance with the Company's internal policies,
has tendered his resignation. The Corporate Governance and
Nominating Committee of the board of directors will study the
matter and make a recommendation to the board of directors
concerning the acceptance of this resignation.
| Nominee |
Votes For |
% For |
Votes
Withheld |
% Withheld |
| Yvon Bastien |
37,981,768 |
22.66% |
826,143 |
0.49% |
| Michael Berendt |
38,594,091 |
23.02% |
213,820 |
0.13% |
| Rod Budd |
37,429,217 |
22.33% |
1,378,694 |
0.82% |
| Lyne Fortin |
36,763,622 |
21.93% |
2,044,289 |
1.22% |
| Greg Gubitz |
17,839,107 |
10.64% |
20,968,804 |
12.51% |
| James Rae |
38,218,108 |
22.80% |
589,803 |
0.35% |
A special resolution amending the articles of the Company to
change the name of the Company to Telesta Therapeutics Inc. to
further align the Company with its brand, was confirmed, ratified
and approved. It is the Company's intention, in the weeks to
come, to make the necessary filings with the relevant regulatory
authorities to effect this name change.
Shareholders at the Meeting also approved the re-appointment of
Bioniche's auditors, Ernst & Young LLP, Chartered
Accountants.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a late clinical
stage Canadian biopharmaceutical company focused on the
development, manufacturing, marketing and licensing/acquisition of
proprietary and innovative therapies for the global human health
market. The Company's primary goal is to develop and commercialize
products that advance human health and increase shareholder value.
For more information, please visit www.Bioniche.com.
Except for historical information, this news
release may contain "forward-looking statements" and
"forward-looking information" within the meaning of applicable
securities laws that reflect the Company's current expectation
regarding future events. Forward-looking statements and information
are necessarily based upon a number of estimates and assumptions
that, while, considered reasonable by management, are inherently
subject to significant business, economic and competitive
uncertainties and contingencies. Readers are cautioned that any
such forward-looking statements and information are not guarantees
and there can be no assurance that such statements and information
will prove to be accurate, and actual results and future events
could differ materially from those anticipated in such statements
and information. These forward-looking statements and information
involve risk and uncertainties, which may cause, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. The Company
expressly disclaims any intention or obligation to update or revise
any forward-looking statements and information whether as a result
of new information, future events or otherwise. All written and
oral forward-looking statements and information attributable to us
or persons acting on our behalf are expressly qualified in their
entirety by the foregoing cautionary statements.
SOURCE Bioniche Life Sciences Inc.